SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Innate Pharma Reports Third-Quarter 2026 Business Update

Innate Pharma said Phase 1 dose-escalation data for its Nectin-4 ADC IPH4502 will be presented at ENA 2026 on November 18.

IPHA

Related stories